Hyderabad, July 23, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Rozerem® brand had U.S. sales of approximately $91.3 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health*.
Dr. Reddy’s Ramelte on Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.
Rozerem® is a trademark of Takeda Pharmaceutical Company Limited.
*IQVIA Retail and Non-Retail MAT May 2019.
Corporate Comm India (CCI Newswire)